Wave Life Sciences (WVE) director files Form 4 for planned share sales

Rhea-AI Filing Summary

Wave Life Sciences Ltd. director Mark Corrigan reported open‑market sales of company ordinary shares under a pre‑arranged Rule 10b5‑1 trading plan. On December 8, 2025, he sold 9,600 ordinary shares at a weighted‑average price of $13.09 per share and later the same day sold an additional 6,515 ordinary shares at a weighted‑average price of $14.065 per share. After these transactions, he beneficially owned 35,330 ordinary shares following the first sale and 28,815 ordinary shares following the second, all held directly. The prices for each block reflect multiple individual trades within stated ranges, and full trade‑level details are available from the reporting person upon request.

Insider Trade Summary

Net Seller: 16,115 shares ($217,297)

Net Sell 2 txns

Insider CORRIGAN MARK

Role Director

Sold 16,115 shs ($217K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	9,600	$13.09	$126K
Sale	Ordinary Shares	6,515	$14.065	$92K

Holdings After Transaction: Ordinary Shares — 35,330 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.69 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.71 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CORRIGAN MARK

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/08/2025		S(1)		9,600(1)	D	$13.09(2)	35,330	D
Ordinary Shares	12/08/2025		S(1)		6,515(1)	D	$14.065(3)	28,815	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.

2. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.69 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.71 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Mark Corrigan	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Wave Life Sciences (WVE) disclose in this Form 4?

The filing reports that director Mark Corrigan sold ordinary shares of Wave Life Sciences Ltd. in open‑market transactions on December 8, 2025 under a Rule 10b5‑1 trading plan.

How many Wave Life Sciences (WVE) shares did the director sell and at what prices?

On December 8, 2025, he sold 9,600 ordinary shares at a weighted‑average price of $13.09 per share and 6,515 ordinary shares at a weighted‑average price of $14.065 per share.

How many Wave Life Sciences (WVE) shares does the director own after these transactions?

After the first sale, he beneficially owned 35,330 ordinary shares, and after the second sale he beneficially owned 28,815 ordinary shares, all reported as held directly.

Were the Wave Life Sciences (WVE) share sales under a Rule 10b5‑1 trading plan?

Yes. The sales were effected under a Rule 10b5‑1 trading plan adopted by the reporting person on August 6, 2025.

What is the price range for the Wave Life Sciences (WVE) shares sold in these transactions?

For the first block, the sale price range was $12.75 to $13.69 per share. For the second block, the price range was $13.75 to $14.71 per share.

Who signed the Wave Life Sciences (WVE) Form 4 and when?

The Form 4 was signed by /s/ Mark Corrigan on December 10, 2025.